Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades,
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …

Background Locally advanced or metastatic urothelial carcinoma is generally incurable and
has scarce treatment options, especially for cisplatin-ineligible patients previously treated …

After cisplatin-based chemotherapy became the standard treatment for metastatic urothelial
cancer (mUC), very little progress has been made in the treatment landscape of this …

Selective defluorinative functionalization of trifluoromethyl ketones is a long‐standing
challenge owing to the exhaustive mode of the process. To meet the demands for the …

Background Electronic collection of patient-reported outcomes (ePROs) is becoming
widespread in health care, but the implementation into routine cancer care during therapy …

Patients with urothelial cell carcinoma (UCC) often have comorbidities, which cause trouble
for the completion of oncological treatment, and little is known about their quality of life …

The selective installation of fluorine-containing groups into biologically relevant molecules
has been used as a common strategy for the development of pharmaceutically active …

Abstract On April 3, 2023, the FDA granted accelerated approval to enfortumab vedotin-ejfv
(EV) plus pembrolizumab for treatment of patients with locally advanced or metastatic …

Cisplatin-based chemotherapy has been the standard of care in metastatic urothelial cancer
(mUC) for more than two decades. However, many patients with comorbidities cannot …

Cisplatin-based chemotherapy has been the standard of care for patients with locally
advanced or metastatic urothelial cancer (la/mUC). Enfortumab vedotin, an antibody-drug …